Morgan Stanley Downgrades Theravance Biopharma to Underweight, Lowers Price Target to $14
Morgan Stanley analyst Vikram Purohit downgrades Theravance Biopharma (NASDAQ:TBPH) from Overweight to Underweight and lowers the price target from $27 to $14.
Mid-Afternoon Market Update: Nasdaq Rises 75 Points; Palo Alto Networks Shares Jump On Upbeat Earnings
Toward the end of trading Tuesday, the Dow traded up 0.26% to 35,427.95 while the NASDAQ rose 0.50% to 15,018.26. The S&P also rose, gaining 0.25% to 4,490.82.
Analysts Slash Price Targets After Theravance’s Failed Ulcerative Colitis Study
Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data.
Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide
Midway through trading Tuesday, the Dow traded up 0.09% to 35,368.20 while the NASDAQ rose 0.40% to 15,001.95. The S&P also rose, gaining 0.14% to 4,486.01.
What 10 Analyst Ratings Have To Say About Theravance Biopharma
Theravance Biopharma (NASDAQ:TBPH) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
38 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Triple-S Management Corporation (NYSE: GTS) shares jumped 45.3% to $35.15. GuideWell Mutual Holding Corporation, parent of Blue Cross and Blue Shield of Florida Inc, will acquire Triple-S Management for an equity value of approximately $900 million.
Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates
Following the market opening Tuesday, the Dow traded up 0.11% to 35,374.12 while the NASDAQ rose 0.43% to 15,006.17. The S&P also rose, gaining 0.22% to 4,489.23.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning trading, 20 companies set new 52-week lows.